Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. (Q54218339)

26 May 2018

title

Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. (English)

1 reference

26 May 2018

1 reference

4

Toshihiko Doi

1 reference

26 May 2018

Atsushi Ochiai

7

Atsushi Ochiai

1 reference

26 May 2018

Takeshi Kuwata

3

Takeshi Kuwata

1 reference

26 May 2018

Atsushi Ohtsu

5

Atsushi Ohtsu

1 reference

26 May 2018

Akiko Kawano Nagatsuma

1

Akiko Kawano Nagatsuma

1 reference

26 May 2018

Masaki Aizawa

2

Masaki Aizawa

1 reference

26 May 2018

Hirofumi Fujii

6

Hirofumi Fujii

1 reference

26 May 2018

publication date

14 March 2014

1 reference

26 May 2018

published in

Gastric Cancer

1 reference

26 May 2018

volume

18

1 reference

26 May 2018

issue

2

1 reference

26 May 2018

page(s)

227-238

1 reference

26 May 2018

Cancer incidence and incidence rates in Japan in 2006: based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project

cites work

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

Obesity and breast cancer prognosis: weight of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma--a rationale for a molecular targeting strategy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

Multidimensional identification of tissue biomarkers of gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

FGFR2 protein expression in breast cancer: nuclear localisation and correlation with patient genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10120-014-0360-4

Co-expression of keratinocyte growth factor and K-sam is an independent prognostic factor in gastric carcinoma.

21 January 2018

1 reference

12 December 2020

HER2 expression and its clinicopathological features in resectable gastric cancer

1 reference

12 December 2020

Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays

1 reference

12 December 2020

The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas

1 reference

12 December 2020

Japanese classification of gastric carcinoma: 3rd English edition

1 reference

12 December 2020

Immunohistochemical detection of K-sam protein in stomach cancer

1 reference

12 December 2020

Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target.

1 reference

12 December 2020

10.1007/S10120-014-0360-4

Identifiers

DOI

1 reference

26 May 2018

1 reference

26 May 2018